Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.Mos.HIV and Clade C gp140 Vaccine Schedules in Healthy Adults
NCT02685020Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2016
- Primary completion
- Jan 2018
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Ad26.Mos4.HIV and clade C gp140 in human immunodeficiency virus infection (HIV) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Titer to HIV-Envelope Specific Binding Antibodies Assessed by Env-Ab-binding Assay, Breadth of HIV-Envelope Specific Binding Antibodies Assessed by Env-Ab-binding Assay and 5 more. Started Mar 2016; status: completed.
02
Drugs
Ad26.Mos4.HIVclade C gp140
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02685020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02685020.